Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control studyLéo Plaçais, Célèste Lebbé, O. Dereure et al.|Annals of the Rheumatic Diseases|2022Cited by 34